U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H20N2O2
Molecular Weight 212.2891
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BRIVARACETAM

SMILES

CCC[C@]1([H])CC(=O)N(C1)[C@@]([H])(CC)C(=N)O

InChI

InChIKey=MSYKRHVOOPPJKU-BDAKNGLRSA-N
InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1

HIDE SMILES / InChI

Molecular Formula C11H20N2O2
Molecular Weight 212.2891
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Brivaracetam (UCB 34714, trade name Briviact), the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam, but with 20-fold greater affinity. There is some evidence that racetams including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis. They may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BRIVIACT

Approved Use

BRIVIACT is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy

Launch Date

1463011200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.5 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.7 μg/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.3 μg/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9 μg/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.2 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.7 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
28 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
55.4 μg × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
90.8 μg × h/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
104.1 μg × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
27.5 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
56 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.3 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.8 h
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.3 h
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.8 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.7 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.3 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
unknown, unknown
BRIVARACETAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Other AEs: Somnolence, Blurred vision...
Other AEs:
Somnolence (severe, 2 patients)
Blurred vision (1 patient)
Dizziness (2 patients)
Agitation (1 patient)
Bradyphrenia (1 patient)
Disorientation (1 patient)
Euphoric mood (1 patient)
Sources:
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Other AEs: Somnolence, Blurred vision...
Other AEs:
Somnolence (2 patients)
Blurred vision (1 patient)
Dizziness (3 patients)
Agitation (1 patient)
Bradyphrenia (1 patient)
Disorientation (1 patient)
Euphoric mood (1 patient)
Sources:
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Sources:
Disc. AE: Convulsion, Somnolence...
AEs leading to
discontinuation/dose reduction:
Convulsion (1.4%)
Somnolence (0.7%)
Depression (0.6%)
Dizziness (0.6%)
Fatigue (0.5%)
Suicidal ideation (0.5%)
Suicide attempt (0.5%)
Sources:
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
healthy, 64.1 years
Other AEs: Somnolence, Dizziness...
2 mg/kg 2 times / day steady, oral
Highest studied dose
Dose: 2 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 2 mg/kg, 2 times / day
Sources:
unhealthy, <8 years
Health Status: unhealthy
Age Group: <8 years
Sex: M+F
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Blurred vision 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Bradyphrenia 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Disorientation 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Euphoric mood 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Dizziness 2 patients
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Somnolence severe, 2 patients
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Agitation 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Blurred vision 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Bradyphrenia 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Disorientation 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Euphoric mood 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Somnolence 2 patients
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Dizziness 3 patients
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
Fatigue 0.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Sources:
Suicidal ideation 0.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Sources:
Suicide attempt 0.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Sources:
Depression 0.6%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Sources:
Dizziness 0.6%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Sources:
Somnolence 0.7%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Sources:
Convulsion 1.4%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Sources:
Dizziness 42.9%
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
healthy, 64.1 years
Somnolence 57.1%
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
healthy, 64.1 years
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 541 uM]
no [IC50 740 uM]
no [Inhibition 200 uM]
no [Inhibition 650 uM]
no [Inhibition 650 uM]
no [Inhibition 650 uM]
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
2004 Jan 29
Antiepileptic drug discovery: lessons from the past and future challenges.
2005
Gateways to clinical trials.
2005 Jan-Feb
Brivaracetam UCB.
2005 Jul
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
2006 Jun
Diverse mechanisms of antiepileptic drugs in the development pipeline.
2006 Jun
Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus.
2007
Gateways to clinical trials.
2007 Dec
Brivaracetam (UCB 34714).
2007 Jan
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).
2007 Jan
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.
2007 Jun
Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model.
2007 Sep 4
Pharmacological management of epilepsy: recent advances and future prospects.
2008
The effectiveness of anticonvulsants in psychiatric disorders.
2008
Gateways to clinical trials.
2008 Apr
Effect of brivaracetam on cardiac repolarisation--a thorough QT study.
2008 Aug
Brivaracetam: a rational drug discovery success story.
2008 Aug
Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
2008 Aug
Treatment of Lennox-Gastaut syndrome: overview and recent findings.
2008 Dec
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
2008 Dec
Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster.
2008 Dec 28
Modifications of antiepileptic drugs for improved tolerability and efficacy.
2008 Feb 14
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects.
2008 Jan
New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels.
2008 Jul
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.
2008 Jul
Gateways to clinical trials.
2008 Mar
Brivaracetam: a new drug in development for epilepsy and neuropathic pain.
2008 Mar
SVOP is a nucleotide binding protein.
2009
What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate.
2009 Dec
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).
2009 Jan
Brivaracetam inhibits spreading depression in rat neocortical slices in vitro.
2009 Jul
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.
2009 Mar-Apr
Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs.
2010 Apr
Gateways to clinical trials.
2010 Apr
Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.
2010 Aug 10
New drugs for pediatric epilepsy.
2010 Dec
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).
2010 Dec
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
2010 Feb 12
Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.
2010 Jan
Gateways to clinical trials.
2010 Mar
Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy.
2010 Mar
Antiepileptic drug interactions - principles and clinical implications.
2010 Sep
Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats.
2010 Sep
Emerging drugs for partial onset seizures.
2010 Sep
Patents

Sample Use Guides

The recommended starting dosage is 50 mg twice daily (100 mg per day). Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day). BRIVIACT (brivaracetam) injection may be used when oral administration is temporarily not feasible. BRIVIACT injection should be administered at the same dosage and same frequency as BRIVIACT tablets and oral solution.
Route of Administration: Other
Brivaracetam (BRV) is able to modulate the voltage-activated Na(+) inflow in cortical neurons. Voltage-activated Na(+) currents were recorded by whole-cell patch-clamp on neuronal somas of rat neocortical neurons, grown in dissociated cell culture for up to 12 days. BRV, dissolved at the desired final concentration (between 0.2 microM and 1 mM) was applied by a multi-barrel pipette system near the soma of the recorded neuron. BRV produced a concentration-dependent inhibition of voltage-dependent Na(+) currents with IC(50) values of 41 microM at the holding potential of -100 mV, and of 6.5 microM at the holding potential of -60 mV. The voltage-dependence of activation and the kinetics of fast inactivation were not modified in the presence of BRV (30 microM).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:35:16 UTC 2021
Edited
by admin
on Fri Jun 25 21:35:16 UTC 2021
Record UNII
U863JGG2IA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BRIVARACETAM
DASH   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
BRIVARACETAM [MART.]
Common Name English
BRIVARACETAM [INN]
Common Name English
BRIVARACETAM [USAN]
Common Name English
BRIVARACETAM [WHO-DD]
Common Name English
BRIVARACETAM [MI]
Common Name English
UCB 34714
Code English
BRIVIACT
Brand Name English
UCB-34714
Code English
(2S)-2-((4R)-2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE
Systematic Name English
(2S)-2-((4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL) BUTANAMIDE
Systematic Name English
1-PYRROLIDINEACETAMIDE, .ALPHA.-ETHYL-2-OXO-4-PROPYL (.ALPHA.S,4R)-
Common Name English
BRIVARACETAM [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/05/315
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
WHO-ATC N03AX23
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
FDA ORPHAN DRUG 207305
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
FDA ORPHAN DRUG 724019
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
FDA ORPHAN DRUG 711119
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
Code System Code Type Description
WIKIPEDIA
BRIVARACETAM
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
DRUG CENTRAL
5068
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
PUBCHEM
9837243
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL607400
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
INN
8642
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
NDF-RT
N0000192345
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY Epoxide Hydrolase Inhibitors [MoA]
NCI_THESAURUS
C65270
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
EVMPD
SUB25397
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
DRUG BANK
DB05541
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
LACTMED
Brivaracetam
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
RXCUI
1739745
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
FDA UNII
U863JGG2IA
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
CAS
357336-20-0
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
MERCK INDEX
M2654
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY Merck Index
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
BINDER->LIGAND
BINDING
TARGET->LIGAND
Related Record Type Details
METABOLITE INACTIVE -> PARENT
AMOUNT EXCRETED
URINE
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE INACTIVE -> PARENT
AMOUNT EXCRETED
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC